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Sebum production is regulated by the opposing effects
of androgens and estrogens. The intracrine activity of
steroid metabolizing enzymes is important in regulating
sebum production because these enzymes can convert
weak steroids from the serum into potent androgens
and estrogens within the sebaceous gland (SG). 17b-
hydroxysteroid dehydrogenase (17b-HSD) interconverts
weak and potent sex steroids via redox reactions. In
this regard, it may function as a gatekeeping enzyme
regulating the hormonal milieu of the SG. Six isozymes
of 17b-HSD have been identified that differ in their
substrate preference and their preference to produce
weak or potent sex steroids via oxidation or reduction,
respectively. The goals of this study are: (i) to identify
which isozyme (s) of 17b-HSD is active in SG; (ii) to
determine if its activity differs in facial skin compared
with nonacne-prone skin that may account for the
regional differences in sebum production; (iii) to compare
the activity of 17b-HSD in intact glands and in SG
homogenates; and (iv) to determine if 13-cis retinoic acid
inhibits 17b-HSD activity. Human SG were assayed for
Sebum production is a key factor in the development ofacne. Potent androgens (C-19 steroids) such as testosteroneand dihydrotestosterone stimulate sebum production whereasclinical doses of estrogen (C-18 steroids) may inhibit itsproduction (Pochi and Strauss, 1976). The local (or intra-
crine) metabolism of sex steroids plays a critical role in establishing the
balance between androgens and estrogens in the sebaceous gland (SG).
At the time of adrenarche, the systemic circulation provides an abundant
reservoir of biologically weak steroids including dehydroepiandro-
sterone sulfate, androstenedione, and estrone. These precursors can be
converted into potent C-19 and C-18 steroids within the SG through
the action of steroid metabolizing enzymes present in SG (Hay and
Hodgins, 1974; Itami and Takayasu, 1981; Simpson et al, 1983; Sawaya
et al, 1988). Because 17β-hydroxysteroid dehydrogenase (17β-HSD)
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17b-HSD activity using estrogens, androgens, and proges-
tins as substrates. Oxidative activity of the type 2 isozyme
predominated in all samples tested. Although transcripts
for the types 1, 2, 3, and 4 isozymes were detected using
reverse transcriptase-polymerase chain reaction, only
mRNA for the predominant type 2 isozyme and the type
4 isozyme were detected in northern analysis. Greater
reductive activity of 17b-HSD was noted in SG from facial
areas compared with nonacne-prone areas, suggesting an
increased net production of potent androgens in facial
areas. Oxidation was more predominant over reduction
in intact SG compared with homogenized SG, thus
supporting the hypothesis that 17b-HSD protects against
the effects of potent androgens in vivo. Activity of the
type 2 17b-HSD was not inhibited by 13-cis retinoic acid.
In conclusion, SG possess the cellular machinery needed
to transcribe the genes for the type 1–4 isozymes of 17b-
HSD. At the protein level, however, oxidative activity of
the type 2 isozyme predominates, suggesting that 17b-
HSD isozyme activity may be translationally regulated.
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catalyzes both the formation of testosterone and estradiol (via reduction)
and the backconversion of these hormones to less active precursors
(via oxidation), its activity may regulate the local availability of potent
sex steroids in the SG and other endocrine target tissues.
In addition to classical biochemical regulation of steroid metabolizing
enzymes (such as pH, availability of substrate and pyridine nucleotide
cofactors, etc.), regulation also exists through the tissue specific
expression of various isozymes of steroid metabolizing enzymes and
even by the action of tissue specific promoters (Simpson et al, 1997)
Six isozymes of 17β-HSD have been identified that differ in their
preference for substrate (androgens, estrogens, or progestins), pH
optima, cofactor specificity, and tissue localization (Luu-The et al,
1989; Adamski et al, 1995; Andersson and Moghrabi, 1997; Biswas
and Russell, 1997). Each isozyme is the product of a unique gene.
There is less than 28% sequence homology among the six isozymes.
The type 1 isozyme of 17β-HSD preferentially reduces estrone to
estradiol using NADPH as a cofactor. It is the predominant isozyme
responsible for estrogen production in the ovary and breast. The type
2 isozyme preferentially oxidizes potent C-19 and C-18 steroids to
weaker androgens and estrogens at alkaline pH using NAD as a
cofactor. It has been localized to the breast, placenta, ovary, prostate,
pancreas, and other tissues. The type 3 isozyme, localized in testis,
preferentially reduces androstenedione to testosterone using NADH
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or NADPH as a cofactor. The type 4 isozyme oxidizes estradiol to
estrone but does not oxidize testosterone, and is a peroxisomal enzyme
found in a wide variety of tissues. The type 5 isozyme of 17β-HSD
has been sequenced in mice (Deyashiki et al, 1995), and is an
aldoketoreductase that preferentially reduces androgens and estrogens
using NADPH as a cofactor (Labrie et al, 1997). A cDNA encoding a
type 6 isozyme was isolated from rat ventral prostate (Biswas and
Russell, 1997), and shares 65% sequence identity with the retinol
dehydrogenase 1 enzyme. It preferentially oxidizes 3α-androstanediol
to androsterone using NAD1 as a cofactor and oxidizes testosterone
and estradiol.
In assaying 5α-reductase activity in human SG, increased back-
conversion of testosterone to androstenedione was noted with increasing
pH, indicating activity of 17β-HSD (Thiboutot et al, 1995). At the
same time, tissue specific expression of 17β-HSD isozymes was being
described. The goals of this study were to identify which isozyme (s)
of 17β-HSD is active in human SG using biochemical parameters,
northern analysis, and the reverse transcriptase-polymerase chain reac-
tion (RT-PCR), and to determine if there are differences in its activity
in acne-prone regions compared with nonacne-prone regions. In
addition, the ratio of oxidative to reductive activity (OX/RED ratio)
of 17β-HSD has been reported to be greater in intact cells compared
with homogenized cells (Luu-The et al, 1995; Castagnetta et al, 1996;
Carruba et al, 1997). The OX/RED ratio obtained in intact glands
may be more representative of the in vivo situation. For this reason,
the biochemical profile of 17β-HSD was compared in intact and
homogenized SG. Furthermore, it has been hypothesized that 13-cis
retinoic acid (13-cis RA), the most potent inhibitor of sebum produc-
tion, acts in part by inhibiting steroid metabolizing enzymes (Boudou
et al, 1995). Activity of the rat type 6 isozyme of 17β-HSD is inhibited
by 13-cis RA in transfected human kidney cells (Biswas and Russell,
1997). These data provided a rationale for examining the effects of
13-cis RA on 17β-HSD activity in SG. Alteration of the activity of
the isozymes of steroid metabolizing enzymes such as 17β-HSD may
represent novel strategies in the treatment of hormonally regulated
skin diseases such as acne, hirsutism, or male pattern hair loss.
MATERIALS AND METHODS
Skin specimens Samples of normal skin were obtained from routine surgeries
performed in the Division of Dermatology at The Pennsylvania State University’s
Hershey Medical Center under a protocol approved by the Institutional Review
Board. Subjects ages ranged from 35 to 85 y of age, with a mean age of 68 y.
Samples were transported and SG were dissected as previously described
(Thiboutot et al, 1995).
Enzyme assays and steroid separation Incubation studies with radiolabeled
steroid substrate were performed on homogenized SG and intact SG isolated
from facial and nonfacial areas in order to determine the specific activity of
17β-HSD. Homogenates of SG were prepared and protein content determined
as previously described (Thiboutot et al, 1995). The incubation cocktail consisted
of 106 dpm of radiolabeled steroid substrate ([1,2–3H]testosterone, [1,2,6,7–
3H]androstenedione, [6,7–3H]estradiol, [6,7–3H]estrone, [1,2–3H]progesterone,
or [1,2–3H]20α-hydroxyprogesterone; Dupont NEN, Wilmington, DE or
Amersham, Arlington Heights, IL) in the presence of 1–10 µM nonradioactive
substrate, 500 µM NADPH, NADP, NADH, or NAD (Sigma, St. Louis, MO),
1 mM dithiothreitol (Sigma), 40–80 µg of homogenate protein in a final
volume of 0.2 ml of succinic acid/imidazole/diethanolamine buffer with pH
adjusted depending on the study being performed. All steroids were purified
using thin layer chromatography prior to use. Unless stated otherwise, reactions
were performed at pH 7.
In all experiments, each sample was assayed in duplicate and a negative
control, consisting of all components of the incubation cocktail except for the
SG sample, was assayed under identical conditions. Each reaction was carried
out at 37°C for 60 min. The reactions in homogenates were terminated by the
addition of 1 ml of cyclohexane/ethyl acetate (70:30, vol/vol) containing
nonradioactive carrier steroids. In studies of intact glands, the reactions were
terminated by removing the glands from the wells. Samples were extracted
twice with chloroform/ethyl acetate (70:30) and the pooled extracts evaporated
under nitrogen. The extracts were dissolved in ethyl acetate (androgens and
progestins) or ethanol (estrogens) prior to chromatographic separation.
Steroids were separated by thin layer chromatography and enzyme activities
were calculated (Thiboutot et al, 1995). The solvent system used for separating
testosterone from androstenedione and progesterone from 20α-hydroxyproges-
terone was chloroform/methanol (99:1, vol/vol), whereas estrone and estradiol
were separated using chloroform/acetone (9:1, vol/vol).
Assay validation Preliminary experiments to determine the optimal incuba-
tion time and linearity of 17β-HSD activity with SG enzyme protein concentra-
tion were performed. SG homogenates from female breast skin were incubated
at pH 7 for 10, 60, and 120 min to determine the optimal incubation time for
this assay. Androgens were used as substrates. These data were used to determine
the time course of the oxidative and reductive activity of 17β-HSD. Incubation
studies with varying quantities of SG homogenate protein (42–340 µg) were
performed in order to demonstrate that the formation of product (androstene-
dione) was linear with the amount of enzyme used.
Biochemical parameters of 17b-HSD activity in SG homogenates In
order to determine which isozyme(s) of 17β-HSD predominates in SG, a series
of experiments was performed to demonstrate the enzyme’s pH optima, cofactor
dependence, preference for substrate, and predominant reaction type (oxidation
or reduction). SG homogenates from breast tissue were incubated at pH 5–12
in order to demonstrate the pH profile of the oxidative and reductive activity
of 17β-HSD using both C-19 and C-18 steroids as substrates. The dependence
of 17β-HSD activity on the presence of cofactor [500 µM NAD, NADP,
NADH, or NADPH (Sigma)] was demonstrated in incubation studies using
C-19 as substrates in homogenized SG from the breast, nose, forehead, and
abdomen. Studies to determine the substrate preference of 17β-HSD were
performed in SG homogenates and in intact SG from a variety of anatomic areas.
17b-HSD activity in intact SG Approximately 70 to 80 SG were freshly
isolated from skin from each of seven subjects. For each subject, SG were
placed in groups of six into wells of a 24 well cell culture plate for a total of
12 groups of glands for each subject. Duplicate groups of glands were assayed
for 17β-HSD activity with one of the following six substrates: testosterone,
androstenedione, estradiol, estrone, progesterone, or 20α-hydroxyprogesterone
(Sigma). Each group of glands was incubated with 106 dpm of radiolabeled
substrate (as above) and 1 µM of nonradioactive substrate in the buffer system
described above. No exogenous cofactors were added. Each group of intact SG
was homogenized after the incubation and the protein content determined. In
all experiments of intact glands, both the oxidative and the reductive activity
of 17β-HSD was determined and the OX/RED ratio was calculated. Com-
parison was made between the ratio obtained in intact SG and in SG
homogenates using a paired t test (α 5 0.05).
Effects of 13-cis RA on 17b-HSD activity To determine if 13-cis RA
inhibits activity of 17β-HSD in human SG, enzyme assay solutions from breast
SG were supplemented with dilutions of 13-cis RA (Sigma) in ethanol to
achieve final concentrations ranging from 0 to 100 µM. Retinoids were handled
under dimmed yellow light. The final concentration of ethanol in each assay
was less than 0.5%, a concentration shown not to affect enzyme activity.
Testosterone (10 µM) was used as a substrate and the incubation was carried
out for 60 min as above.
Northern analysis Biochemical data suggested that the type 2 isozyme
predominated in SG. Northern analysis was performed in order to confirm
these data and to determine if messenger RNA from any of the other isozymes
could be detected in human SG. Two hundred and fifty SG isolated from eight
subjects were pooled, snap frozen in liquid nitrogen, and stored at –80°C.
RNA from these glands and from homogenates of control tissues (breast
parenchyma, prostate, and placenta) was isolated (Chomczynski Sacchi, 1987).
Twenty micrograms of total RNA from each sample were electrophoresed on
a 1% agarose gel and transferred to a nylon membrane. A riboprobe complement-
ary to the type 1 17β-HSD was generated from the full-length cDNA provided
by Dr. Van Luu-The (Laval University, Quebec City). Inserts corresponding to
the full-length transcripts for the types 2 and 3 17β-HSD were cut from the
pCMV6 plasmids provided by Dr. Stefan Andersson (South-western Texas
University, Dallas, TX). These were labeled with 23P dCTP by random priming
(Feinberg and Vogelstein, 1983; Feinberg and Vogelstein, 1984). A probe for
the type 4 isozyme of 17β-HSD was generated by random priming from the
cDNA provided by Dr. Jerzy Adamski (GSF National Research Center,
Neuherberg, Germany). The nylon membrane was hybridized with probe for
24 h at 42°C, washed under low and high stringency conditions, and exposed
to X-ray film (Sambrook et al, 1989). After each use, the membrane was
stripped of radioactive probe and this procedure was verified by exposure to
X-ray film before hybridizing to the next probe. The membrane was hybridized
with a radiolabeled probe for 18S RNA to assure equal loading of RNA samples.
Synthetic oligonucleotides The following primers were chosen for each of
the four isozymes of 17β-HSD from published sequences (Luu-The et al, 1989;
Wu et al, 1993; Geissler et al, 1994; Adamski et al, 1995): type 1 (Genbank
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Figure 1. pH profile of 17b-HSD in homogenates of SG obtained from
female breast tissue. (A) Oxidative activity (u) and reductive activity (e)
using androgens as substrates and (B) oxidative (u) and reductive activity (e)
using estrogens as substrates. Values represent the mean of two determinations.
#X13440)FP: 59 CTACCAATACCTCGCCCACA; type 1 RP:59GGTGAAG-
TAGCGCAGGGTCG; type 2 (Genbank #L1708) FP: 59AAGGCTGGCAT-
CTTATGGCT; type 2 RP 59TTCCCACTTGTCACTGGTGCCTGCGAT-
ATT; type 3 (Genbank #U05659) FP: 59 ATCCATTGTAACATCACCTC,
type 3 RP 59GGATGATGACTTCTTTTGCT; type 4 (Genbank #X87176)
FP: 59ATCAGCTTCAGGAATATATG; and type 4 RP 59CAAGATCTT-
CAGGCATAACT. The lengths of the DNA segments to be amplified were
121 base pairs, 151 base pairs, 211 base pairs, and 181 base pairs, respectively,
for each of the types 1–4 isozymes.
Reverse transcription and polymerase chain reaction (PCR) Total
RNA was isolated from two samples of SG, each pooled from facial areas of
15 subjects (Chomczynski and Sacchi, 1987). First strand cDNA synthesis was
performed using a First-Strand cDNA Synthesis kit (Pharmacia, Piscataway,
NJ). Briefly, four 1 µm aliquots of each RNA sample were each diluted in 8 µl
of sterile distilled water, heated to 65°C for 10 min, and cooled on ice.
Moloney-mouse-leukemia virus reverse transcriptase 20 u (Pharmacia), 50 pmol
of reverse primer, 15 mM dithiothreitol, bovine serum albumin, and dNTP.
Samples were incubated at 37°C for 1 h. The polymerase chain reaction was
initiated. The reaction product (15 µl) was then heated to 95°C for 5 min and
placed on ice. Taq polymerase 2.5 units (Promega, Madison, WI) and 50 pmol
each of forward and reverse primers were added in a final volume of 50 µl of
sterile water. The PCR conditions were set up as follows: 95°C for 5 min,
95°C for 1 min, 58°C for 1 min, 72°C for 1 min. Thirty cycles between steps
2 and 4 were performed. Final extension was performed at 72°C for 10 min.
The annealing temperature used for the type 1 primer was 58°C. PCR products
were separated by electrophoresis on a 2% agarose gel. Bands were cut from
the gel, and DNA was extracted and ligated into a pCR-2.1 vector (Invitrogen,
Carson City, CA) containing an ampicillin resistance gene and lacZα fragment
to allow for blue-white screening. Plasmids were transformed into competent
cells and colonies were selected based on ampicillin resistance and β-galactosidase
activity. Plasmid DNA was prepared from an overnight culture and sequenced
for verification using the M-13 reverse primer using an automated DNA
sequencer with fluorescent tag (ABI Prism 377, Perkin Elmer, Foster City, CA).
RESULTS
Biochemical parameters of 17b-HSD in homogenized SG are
consistent with activity of the type 2 isozyme Linearity of
enzyme activity with time and protein concentration was demonstrated
between 10 and 120 min and 40 and 300 µg protein, respectively
(data not shown). The pH profile of the oxidative and reductive
activity of 17β-HSD in homogenized SG from the female breast was
determined using both C-19 and C-18 steroids as substrates (Fig 1).
With each substrate oxidative activity was sensitive to pH, with optimal
activity noted at pH 10. Optimal reductive activity was noted at
pH 5.0. For C-19 steroids, reductive activity changed little with pH.
The cofactor preference for the oxidative and reductive reactions
of 17β-HSD in SG homogenates using androgens as substrates is
demonstrated in Table I. Oxidative activity of 17β-HSD is greatest
with the cofactor NAD in all samples tested. Reductive activity did
not show a preference for either NADH or NADPH.
The preference of 17β-HSD for substrate was demonstrated in
homogenized SG from facial areas. Seven homogenates were prepared
by pooling µ200–300 SG from a particular anatomic area: two
homogenates each were prepared from male cheek and male nose and
Table I. Sebaceous glands oxidize androgens using NAD as a
cofactora
Specific activity (pmol per min per mg protein)b
T → androstenedionec androstenedione → T 1 DHTc
(oxidation) (reduction)
Tissue NAD NADP NADH NADPH
Breast 16.3 1.1 7.4 7.7
(13.4, 19.3) (1.2, 1.0) (6.6, 8.2) (9.1, 6.3)
Nose 45.8 7.7 33.3 32.8
(45.7, 45.8) (7.5, 7.9) (32.6, 33.8) (34.9, 30.5)
Forehead 14.5 0.87 6.7 4.7
(15.3, 13.7) (0.7, 0.9) (4.0, 7.2) (4.7, 4.7)
Abdomen 55.7 14.4 21.1 18.1
(52.6, 58.8) (14.7, 15.9) (19.8, 22.3) (13.9, 19.1)
aHomogenates of SG from various areas were assayed for the oxidative and reductive
activity of 17β-HSD using 10 µM substrate and 500 µM cofactor.
bData represent mean (range) of two determinations.
cT, testosterone; DHT, dihydrotestosterone.
Table II. Homogenized and intact SG prefer to oxidize
androgens and estrogensa
Homogenized SG Intact SG
Substrate Activityb OX/REDc Activityb OX/REDc
Testosterone 10.0 6 0.94 1.38 6 0.06 0.49 6 0.13 3.2 6 1.0
Androstenedione 7.37 6 0.75 0.14 6 0.04
Estradiol 12.1 6 0.98 1.44 6 0.11d 1.06 6 0.22 7.74 6 1.9d
Estrone 8.5 6 0.9 0.18 6 0.03
aSeven samples of sebaceous glands from facial areas described in the text were assayed
at pH 7 in homogenized and in intact SG for the oxidative and reductive activity of 17β-
HSD using C-19 and C-18 as substrates (1 µM). Cofactor (500 µM) was added in assays
of homogenates, but not intact glands.
bSpecific activity (pmol per min per mg protein). Data expressed are mean 6 SEM of
seven determinations.
cOX/RED ratio represents the mean ratio (6SEM) of the specific activity obtained
using testosterone or estradiol as a substrate divided by the specific activity using
androstenedione or estrone as substrates, respectively. Ratios obtained with each of the
seven data sets were used to determine the mean.
dThe OX/RED ratio obtained in intact glands using estrogens as substrates was
significantly greater than the ratio obtained in homogenized glands, p 5 0.03, paired t
test, α 5 0.05.
one homogenate each from male forehead, female cheek, and female
forehead. Each homogenate was assayed in duplicate using C-19, C-18,
and C-21 (progestins) steroids as substrates (Table II, C-21 data not
shown). Specific activity of 17β-HSD was greatest using estradiol as a
substrate followed by testosterone, estrone, androstenedione, pro-
gesterone, and 20α-hydroxyprogesterone, respectively. The specific
activity of 17β-HSD with C-18 steroids as substrates was µ20% higher
compared with C-19 steroids. Oxidation was the preferred reaction
type in all samples tested. The ratio (mean 6 SEM) of oxidative
activity to reductive activity was 1.38 6 0.06 with C-19 steroids and
1.44 6 0.11 with C-18 steroids.
Northern analysis of SG RNA reveals hybridization to the type
2 probe Using total SG RNA, a hybridization signal was noted
with probe to the type 2 isozyme of 17β-HSD (1.5 and 2.2 kb
transcripts) and the type 4 isozyme (1.4 kb) but not with probes to
the types 1 or 3 isozymes (Fig 2). Hybridization signals and transcript
sizes in control tissues were consistent with published reports (Luu-
The et al, 1989; Wu et al, 1993; Geissler et al, 1994; Adamski et al
1995; Zhang et al, 1996). Hybridization to the type 1 probe was noted
in prostate, placenta, and breast tissue (2.2 kb transcripts in prostate
and breast and 1.3 kb transcripts in all three). Hybridization with the
type 2 probe was noted in prostate, placenta, and breast (1.5 kb and
2.2 kb transcripts). The type 3 probe hybridized to RNA in prostate,
placenta, and breast (1.0 kb transcripts in prostate and breast and 1.3 kb
transcripts in all three) and the type 4 probe hybridized to RNA in
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Figure 2. Northern analysis reveals hybridization of the type 2 probe
with SG RNA from facial regions. Blot hybridization of human SG, prostate,
placental, and breast RNA with 17β-HSD types 1, 2, 3, and 4 probes. Total
RNA (20 µg) from human SG, prostate, placenta, and breast (lanes 1–4,
respectively) were subjected to electrophoresis in the presence of formaldehyde
and blotted to a nylon membrane. The membrane was hybridized using high
stringency conditions with 32P-labeled probes (106–107 counts per min per ml)
complementary to the entire 17β-HSD cDNA inserts. The membrane was
exposed to X-ray film with two intensifying screens for varying times at –80°C.
Figure 3. Amplified sequences consistent with types 1, 2, 3, and 4 17b-
HSD are detected in SG by RT-PCR. Total RNA was extracted from
microdissected SG. cDNA was synthesized and PCR was performed for each
of the four isozymes of 17β-HSD. SG RNA was run as a negative control in
the PCR reaction. M, 100 bp markers; 1, type 1 reaction; 2, type 2 reaction;
3, type 3 reaction; 4, type 4 reaction and C, SG RNA. Expected sizes of
amplified sequences based on primer design were 121 bp for type 1, 151 bp
for type 2, 211 bp for type 3, and 181 bp for type 4.
prostate (1.4 and 2.7 kb transcripts) and SG as above. Subsequent
hybridization of this membrane with 18S RNA indicated that compar-
able amounts of intact RNA were loaded in each lane.
Types 1, 2, 3, and 4 isozyme transcripts are detected using RT-
PCR PCR products from the four reactions from each RNA sample
were separated on a 2% agarose gel. Three bands (400 bp, 200 bp, and
121 bp) were noted when primers amplifying the type 1 sequence
were used (Fig 3, lane 2). Using primer to the type 2 isozyme, a single
distinct band of µ151 bp was noted (Fig 3, lane 3). In the reaction
amplifying a type 3 sequence, a distinct band of µ211 bp and a faint
band of µ120 bp were noted (Fig 3, lane 4). A 181 bp band was
Figure 4. SG from nonacne-prone regions exhibit greater oxidative
activity than SG from the face. Oxidative and reductive activities of 17β-
HSD were assayed in 11 homogenates from facial regions and six homogenates
from nonfacial (nonacne-prone) regions using androgens as substrates at pH 7,
10 µM substrate and 500 µM NAD1 or NADH. Data represent the mean
(6SEM) of 11 facial samples and six nonacne-prone samples. The OX/RED
ratio in nonacne-prone samples was significantly higher than the ratio obtained
in homogenates from nonacne-prone areas (p 5 0.05, paired t test, α 5 0.05).
noted using primers to the type 4 sequence (Fig 3, lane 5). No signal
was noted in the control lane wherein SG RNA was run in the PCR
reaction without prior reverse transcription (Fig 3, lane 6). Each of
the bands noted were cut from the gel. DNA was isolated, cloned into
a pCR2.1 vector (Invitrogen, Carson City, CA), and sequenced, which
revealed homology of the 121 bp fragment of the type 1 reaction with
the target type 1 sequence; the 151 bp fragment of the type 2 reaction
with the target type 2 sequence; the 211 bp fragment with the target
type 3 sequence and homology of the 181 bp fragment with the target
sequence for the type 4 isozyme. The faint 120 bp band in the lane
for the type 3 isozyme was sequenced and revealed only primer
fragments. Remaining sequences from the type 1 reaction were not
homologous with published sequences as reported in Genbank.
Oxidative activity of 17b-HSD was greater in SG from nonacne-
prone regions In addition to the seven homogenates from facial
areas depicted in Table II, an additional four homogenates from acne-
prone regions of skin were prepared by pooling 100–200 SG each
from male cheek, male nose, male forehead, and male scalp. Six
homogenates from nonacne-prone regions were prepared in the same
way by pooling 100–200 SG from each of the following areas: female
breast (two), female abdomen (one), male leg (one), male distal arm
(two). These homogenates from acne-prone and nonacne-prone regions
were assayed in duplicate for oxidative and reductive 17β-HSD activity
using C-19 steroids as substrates. The oxidative activity of 17β-HSD
(mean 6 SEM) in SG homogenates from facial areas was 18.7 6 4.3
(n 5 11), compared with 33.5 6 6 (n 5 6) in homogenates obtained
from nonfacial areas (Fig 4). Although the mean oxidative activity is
higher in homogenates from nonfacial areas compared with facial areas,
this difference did not reach statistical significance (p 5 0.11). There
were no regional differences noted in the reductive activity of 17β-
HSD. The OX/RED ratio (mean 6 SEM) of 17β-HSD in nonacne-
prone regions, however, was significantly higher than the ratio obtained
in glands from facial regions (2.53 6 0.7 vs 1.56 6 0.4, p 5 0.03,
paired t test, α 5 0.05).
13-cis RA does not inhibit 17b-HSD in SG No inhibition of
17β-HSD oxidative activity was noted at any of the concentrations of
394 THIBOUTOT ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
Figure 5. 13-cis RA does not inhibit 17b-HSD activity in human SG.
Sebaceous glands from female breast skin were pooled, homogenized, and
assayed for oxidative activity of 17β-HSD using 10 µM testosterone as a
substrate in the presence of varying concentrations of 13-cis RA. Data represent
the mean of two determinations.
13 cis-RA (0–100 µM) examined in a homogenate of pooled SG from
female breast skin (Fig 5).
Oxidative activity of 17b-HSD is more predominant in intact
SG compared with homogenized SG Activity of 17β-HSD was
assayed in seven separate samples of intact SG obtained from facial
regions corresponding to sites from which the homogenates were
prepared for the substrate preference studies (see above). Overall, the
specific activity of 17β-HSD was lower in intact glands compared with
SG homogenates (Table II). As in the case of the homogenized glands,
C-19 and C-18 steroids were preferred over C-21 steroids as substrates
in intact glands. Oxidative activity of 17β-HSD was preferred over
reductive activity in intact SG. The OX/RED ratio (mean 6 SEM)
was significantly greater in intact glands than in homogenized glands
(paired t test, p 5 0.03, α 5 0.05) (Table II).
DISCUSSION
Although androgens stimulate sebum production; serum levels of
androgens are normal in most acne subjects. Therefore, the local
production of androgens via steroid metabolizing enzymes may be
important in regulating sebum production and the development of
acne. The enzyme 5α-reductase is active in SG where it converts
testosterone to the more potent androgen, dihydrotestosterone, which
is thought to stimulate sebum production. SG from acne-prone areas
demonstrate greater activity of 5α-reductase compared with SG from
nonacne-prone areas (Thiboutot et al, 1995). Because 17β-HSD uses
testosterone as a substrate it may limit the availability of testosterone
as a substrate for 5α-reductase. In this regard, oxidative activity of
17β-HSD may protect the SG from the effects of potent androgens
and estrogens. A similar hypothesis has been proposed regarding the
function of the type 2 isozyme of 17β-HSD in other endocrine target
tissues (Andersson and Moghrabi, 1997).
Each isozyme of 17β-HSD has a unique biochemical profile. In our
study, C-19, C-18, and C-21 steroids were used as substrates for both
the oxidative and the reductive activity of 17β-HSD in SG from a
variety of areas. The enzyme preferred to oxidize androgens and
estrogens at alkaline pH using NAD as a cofactor. It also exhibited
20α-hydroxylase activity. These biochemical data are most consistent
with that of the type 2 isozyme of 17β-HSD (Wu et al 1993). The
activity of 17β-HSD was previously studied in SG using C-19 steroids
as substrates only (Hay and Hodgins, 1978; Itami and Takayasu, 1981;
Hay et al, 1982). These studies were done prior to the identification
of the six isozymes of 17β-HSD. Oxidation of testosterone was the
preferred reaction at an alkaline pH optima in the presence NAD1 as
a cofactor. This profile is also most consistent with that of the type
2 isozyme.
Northern analysis detected transcripts for the types 2 and 4 isozymes
but not for the types 1 or 3. The membrane was not probed with
sequences for the types 5 or 6 isozymes as the human sequences are
not yet available. Biochemical data, however, indicate that it is unlikely
that the type 5 isozyme is active in SG. The possibility of activity of
the type 6 isozyme cannot yet be excluded.
RT-PCR amplification of target sequences in the types 1 and 2
isozymes have been reported in human sebaceous glands (Courchay
et al, 1996). The primers chosen in our study resulted in successful
amplification of sequences homologous to the types 1, 2, 3, and 4
isozymes in SG obtained from facial areas. These data indicate that
transcription of the genes encoding the types 1–4 isozymes of 17β-
HSD can take place in human SG. Our northern and biochemical data
suggest that the type 2 isozyme predominates at both the message and
the protein level. Similar observations have been made in the ovary and
in meningiomas, wherein transcripts for the biochemically predominant
isozyme were noted by both northern analysis and RT-PCR. Transcripts
for less prominent isozymes in these tissues were detected only by RT-
PCR (Carsol et al, 1996; Zhang et al, 1996).
In addition to tissue-specific differences in expression, the activity
of 17β-HSD isozymes can be locally regulated by factors such as pH
and substrate and cofactor availability. The oxidative activity of 17β-
HSD is most tightly controlled by pH with a sharp increase in its
activity as physiologic pH is approached, suggesting that oxidation
predominates in vivo. Substrate availability can be influenced by the
serum concentrations of androgen precursors and by the activity of
other steroid metabolizing enzymes. The cofactor NAD is 2–3-fold
more prevalent than NADP(H) in SG (Im and Hoopes, 1974). This
would also favor the oxidative activity of 17β-HSD and thereby limit
availability of the more potent C-19 and C-18 steroids.
In SG from acne-prone areas, the OX/RED ratio of 17β-HSD is
significantly less than the ratio in SG from nonacne-prone areas,
suggesting that more testosterone is being made available for conversion
to dihydrotestosterone by 5α-reductase in acne-prone areas. These
data, in combination with data demonstrating increased 5α-reductase
activity in facial SG, support the hypothesis that regional differences
exist in the capacity of SG to metabolize androgens (Thiboutot et al,
1995). SG from acne-prone areas may be programmed to produce
larger quantities of potent androgens and hence more sebum. It is
possible that these differences may be magnified in skin affected by acne.
Several investigators have stressed the importance of studying the
activity of 17β-HSD in intact cells rather than in homogenates. Enzyme
activity in intact cells depends upon the availability of endogenous
cofactors, whereas cellular homogenates are supplied with excess
concentrations of cofactor. The cellular compartmentalization and
intracellular pH gradient are disrupted in homogenates as well. Our
data demonstrate that the oxidative activity of 17β-HSD is preferred
in both cellular homogenates and intact SG. The oxidative to reductive
ratio of 17β-HSD was several fold higher in intact glands than in SG
homogenates for both C-19 and C-18 steroids, indicating that the
dominant oxidative activity of 17β-HSD is even more pronounced in
intact cells. This is in concordance with the observation that the
magnitude of the differences in the oxidative and reductive activities
of 17β-HSD are amplified in intact cells compared with homogenized
cells. From a technical standpoint, however, assay of intact glands is
more difficult as glands need to be dissected from fresh tissue and
directly assayed.
The activity of 17β-HSD can be regulated by retinoids, growth
factors, and cytokines (Duncan et al, 1994; Ghersevich et al, 1994;
Reed et al, 1994). 13-cis-RA has been reported to competitively
inhibit activity of 17β-HSD in lysates of human embryonic kidney
cells transfected with the type 6 isozyme (Biswas and Russell, 1997).
No direct inhibition of type 2 17β-HSD activity by 13-cis-RA was
noted in our study. These data lend further support to the hypothesis
that a reduced serum level of androgens in subjects treated with 13-
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cis RA results from a reduction in the amount of SG tissue capable of
producing androgens rather than by inhibition of steroid metabolizing
enzymes (Lookingbill et al, 1992).
Although androgens have been the focus in the hormonal regulation
of the SG, systemic administration of estrogens is known to inhibit
sebum production (Pochi and Strauss, 1976). It is not known if
estrogens oppose the effects of androgen on sebum production directly
or via a feedback mechanism. The demonstration that the type 2
isozyme of 17β-HSD can interconvert weak and potent C-19 and
C-18 steroids within the SG supports the concept that this enzyme
may regulate the net effect of sex steroids locally.
In conclusion, 17β-HSD may be a gatekeeping enzyme that regulates
the balance of potent androgens and estrogens within the SG. In normal
SG, the type 2 isozyme predominates resulting in backconversion of
C-19 and C-18 steroids to less potent forms. Because the net effect of
17β-HSD activity can be modulated by serum levels of precursor
steroids, cytokines, retinoids, and the redox state of the tissue, its
directional activity may differ in skin affected by acne. Agents that
further promote the oxidative activity of 17β-HSD or inhibit its
reductive function may be of value in the treatment of hormonally
regulated skin diseases such as acne.
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